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Multicentric Prospective Study on the Prevalence
of Sublevel IIB Metastases in Head and Neck Cancer
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Fausto Chiesa, MD; Raul Pellini, MD; Giuseppe Spriano, MD; Piero Nicolai, MD
Objective: To evaluate the prevalence of sublevel IIB
lymph node (LN) metastases for head and neck primary
tumors in a large cohort of patients.
Design: Prospective study.
Setting: One referral university hospital and 2 national
institutes of oncology.
Patients: Between 2003 and 2005, 297 patients (male
to female ratio, 3.5:1; mean age, 58.8 years [range, 18-89
years]) affected by head and neck cancer were treated by
surgery on the primary tumor and/or the neck. Primary
site distribution included the following: oral cavity in 111
patients, larynx in 92, oropharynx in 32, thyroid gland
in 22, skin of the lateral face or scalp in 16, hypophar-
ynx in 11, unknown primary in 7, and parotid gland in
6. Sublevel IIB was evaluated for the number of LNs and
pathologic N (pN) status.
Interventions: All patients underwent unilateral or bi-
lateral neck dissection (ND) with therapeutic or elec-
tive intent according to the primary site and clinical T
(cT) and clinical N (cN) status. Sublevel IIB was selec-
tively dissected at the beginning of ND, labeled, and pro-
cessed independently.
Main Outcome Measures: The distribution of me-
tastases among the different levels was analyzed. The in-
fluence of several factors (institution in which the sur-
gical procedure was performed, sex of the patient, site
of primary, histotype, pathologic T [pT] status, cN sta-
tus, lower level involved in the neck together with sub-
level IIB, association with sublevel IIA metastasis, ipsi-
lateral number of involved levels, and previous surgical
treatment limited on the primary site) on the preva-
lence of sublevel IIB metastasis was statistically evalu-
ated by the Pearson ² test or Fisher exact test.
Results: A total of 443 NDs were performed (unilateral
in 151 patients and bilateral in 146). Among the patients,
the tumorswere stagedcN0/pN0 in27%,cN/pN in50%,
cN/pN0 in 7%, and cN0/pN in 16%. The mean num-
ber of LNs collected at sublevel IIB was 5.4 (range, 0-24).
The overall prevalence of sublevel IIBmetastaseswas 5.6%
(26neck sides). Tumorhistologic type in the sublevel IIB
population was squamous cell carcinoma in 80%, papil-
lary carcinoma in 8%, melanoma in 8%, and adenocarci-
noma in 4%. The ² test showed a significantly higher risk
for LNmetastases at sublevel IIB in patients affected by pa-
rotid gland primary tumors (33%), tumors of the skin or
scalp (25%), unknown primary tumors (14%), and can-
cers of the oral cavity (10%) (P=.02) and in those clini-
cally staged as cN (P .001).
Conclusions: Sublevel IIB dissection is strongly recom-
mended for all patients with cN tumors and in those
affected by tumor of the parotid gland, skin, and scalp
scheduled for elective ND. Patients affected by laryn-
geal cancer scheduled for elective ND can be considered
the ideal candidates for preservation of sublevel IIB. How-
ever, whether this policy could be associated with a bet-
ter functional outcome remains to be demonstrated by
prospective studies on a large series of patients.
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I N 1905 AND 1906, GEORGECrile1,2 published 2milestone ar-ticles emphasizing the crucial roleof cervical lymph node (LN)me-tastasis in the natural history and
prognosis of head and neck tumors. He as-
serted that a “block dissection” of all lym-
phatic structures from level I to V encom-
passing the sternocleidomastoid muscle,
the internal jugular vein, and the spinal
accessory nerve had to be systematically
performed to improve the survival rate for
patientswith clinical N (cN) tumors and
those with cN0 tumors.1,2 The idea that
neck dissection (ND) may be modulated
in relation to specific clinical settings was
subsequently developed by HayesMartin,
who introduced the concept of partialND.3
Over the next decades, functional (or
modified radical)4,5 and selective NDs6
were introduced with the intent to com-
bine the oncologic control of disease with
improved functional results.
Recently, technical advances in preop-
erative neck evaluation by ultrasound
sonography, computed tomography, and
magnetic resonance imaging, a better un-
derstanding ofmetastatic spread along the
different levels and sublevels, and the ob-
servation of persistent shoulder func-
Author Affiliations:
Department of
Otorhinolaryngology, University
of Brescia, Brescia, Italy
(Drs Bolzoni Villaret, Piazza,
Peretti, and Nicolai); Head and
Neck Department, European
Institute of Oncology, Milan,
Italy (Drs Calabrese, Ansarin,
and Chiesa); and Department of
Otorhinolaryngology, Regina
Elena Institute of Oncology,
Rome, Italy (Drs Pellini and
Spriano).
(REPRINTED) ARCH OTOLARYNGOL HEAD NECK SURG/VOL 133 (NO. 9), SEP 2007 WWW.ARCHOTO.COM
897
©2007 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universita degli di Milano User  on 03/28/2019
tional impairment even after spinal accessory nerve–
sparing procedures, led to the suggestion of performing
a highly selective ND in specific clinical settings, with
preservation of submuscular recess fat pad referred to as
sublevel IIB.7-18
We report herein the results of the largest prospective
study, to our knowledge, on patients with head and neck
cancer scheduled for sublevel IIB fat pad dissection prior
to completion of the surgical procedure on the neck, with
the purpose of evaluating the prevalence of metastasis at
this site in elective as well as in therapeutic NDs.
METHODS
Between January 2003 and December 2005, 297 consecutive
patients (male to female ratio, 3.5:1; mean age, 59 years [range,
18-89 years]) affected by head and neck cancer were treated
by surgery on the primary site and/or the neck in 3 different
Italian centers: the Department of Otorhinolaryngology at the
University of Brescia in Brescia, the Head and Neck Depart-
ment at the European Institute of Oncology in Milan, and the
Department of Otorhinolaryngology at the Regina Elena Insti-
tute of Oncology in Rome.
The inclusion criteria for the study were no previous sur-
gery on the lateral compartment of the neck for either benign
or malignant lesions, no previous radiation therapy or induc-
tion chemotherapy for the malignant neoplasm considered, no
previous surgical and/or radiation treatment for other head and
neck primary tumors, and the technical feasibility of isolation
and dissection of sublevel IIB fat pat from the remainder of the
ND (ie, patients with massive metastatic localization involv-
ing level II were excluded).
All primary tumors and neck metastases were staged ac-
cording to the sixth edition of the American Joint Committee
on Cancer TNM staging system.19
In general, bilateral ND was performed in all cases of med-
ullary carcinoma, in papillary carcinomas with evidence of bi-
lateral nodal disease, and in those squamous cell carcinomas
(SCCs) of the upper aerodigestive tract crossing the midline
or with preoperative detection of contralateral suspicious LNs.
The extent of ND was modulated according to the site of the
primary and clinical neck status. Clinical staging of the neck
was accomplished by physical examination, combined with ul-
trasound sonography, computed tomography, ormagnetic reso-
nance imaging. Neck dissections were classified according to
the latest ND classification update.20
The sublevel IIB fat pad was isolated and dissected at the
beginning of the surgical procedure, according to the ana-
tomic landmarks provided in the latest ND classification up-
date20: starting from the level of the skull base and dissecting
posterior and lateral to the vertical plane defined by the spinal
accessory nerve back to the posterior border of the sternoclei-
domastoid muscle. The muscular fascia of the levator scapu-
lae and splenius defined the deep plane of dissection. The LNs
isolated over and behind the spinal accessory nerve were al-
ways included in sublevel IIB. Once dissected, the fat pad was
removed before completing the remainder of the ND, labeled,
and processed separately for histopathologic permanent sec-
tion analysis. This procedure was applied with the specific in-
tent to minimize the bias deriving from separating sublevel IIB
from the entire ND specimen without precise anatomic mark-
ers. The NDwas subsequently completed and the specimen di-
vided in the different levels by the surgeon to improve the ac-
curacy in localization of metastatic disease. All levels were
histopathologically evaluated in standard fashion by assessing
the overall number of LNs, the number of metastatic LNs, and
the presence of extracapsular spread. As agreed by the differ-
ent pathologists involved in the study, serial sections of the speci-
men were obtained to identify the lymphatic tissue. The LNs
were harvested, and 1 or 2 slices (in relation to LN size) were
obtained at the level of the longest axis of each isolated node
and stained with hematoxylin-eosin.
Statistical analysiswas performedusing a commercially avail-
able computer software package (SPSS for Windows version
10.0.1; SPSS Inc, Chicago, Illinois). The influence of different
factors (institution in which the surgical procedure was per-
formed, sex of the patient, site of primary, histotype, patho-
logic T [pT] status, cN status, lower level involved in the neck
together with sublevel IIB, association with sublevel IIA me-
tastasis, ipsilateral number of involved levels, and previous treat-
ment) on the prevalence of sublevel IIB metastasis was statis-
tically evaluated by cross-tabulation using the Pearson ² test
or Fisher exact test when at least 1 cell was expected to count
less than 5. P.05 was considered significant.
RESULTS
Awide spectrumof primary sites and histologic typeswith
different propensity to lymphatic spread were included.
The primary site distribution included the following: oral
cavity in 111 patients (38%), larynx in 92 (31%), orophar-
ynx in 32 (11%), thyroid gland in 22 (8%), skin of the lat-
eral face or scalp in 16 (5%), hypopharynx in 11 (4%), un-
known primary in 7 (2%), and parotid gland in 6 (2%).
Thehistologic typeof the lesionswas SCC in90%(n=267),
papillary carcinoma in 5% (n=15), medullary carcinoma
in 2%(n=7), and adenocarcinomaof the parotid gland and
melanoma of the skin of the lateral face and scalp in 1.5%
(n=4) each.
A total of 443 NDs (unilateral in 151 patients and bi-
lateral in 146)were performed in 166 patientswith a clini-
cally positive neck and in 131 for an elective purpose. Sur-
gery on the neck included 11 radical NDs from level I to V
including the internal jugular vein, sternocleidomastoid
muscle, and spinal accessory nerve; 127 modified radical
NDs from level I to V preserving 1, 2, or 3 of the afore-
mentioned nonlymphatic structures; and 305 different se-
lectiveNDs. Taking into account the entire population, the
tumors were staged cN0/pathologic N (pN)0 in 27% (true
negatives), cN/pN in 50% (true positive), cN/pN0 in
7% (false positive), and cN0/pN in 16% (occult metas-
tasis). These data are summarized in relation to the site of
the primary tumor in Table 1.
The mean number of LNs isolated at sublevel IIB was
5.4 (range, 0-24). The overall prevalence of sublevel IIB
metastases was 8.4% and 5.8%when patients (25 of 297)
or neck sides (26 of 443) were considered, respectively
(Table 2). The oral cavity was the site of primary tu-
mor in 11 cases (10 cN and 1 cN0), skin of the lateral
face and scalp in 4 (4 cN), oropharynx in 2 (1 cN
and 1 cN0), larynx in 2 (1 cN and 1 cN0), parotid gland
in 2 (2 cN), thyroid gland in 2 (2 cN), hypopharynx
in 1 (1 cN), and unknown primary in 1 (1 cN). Only
1 case of bilateral involvement of sublevel IIB was ob-
served (see patient 22 in Table 2). Adjunctive details con-
cerning the different levels involved in association with
sublevel IIB are listed in Table 2.
The histologic type in the sublevel IIBpopulationwas
SCC in 80% of patients, papillary carcinoma in 8%, mela-
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noma in 8%, and adenocarcinoma in 4%. All 3 cases (1%
of the patient population and 0.7% of the dissected neck
sides) that were cN0/pN at sublevel IIB (2 pN1 and 1
pN2b) had a locally advanced SCC of the upper aerodi-
gestive tract (see patients 6, 17, and 19 in Table 2). In 2
cases,metastasis exclusively involved 1 LN at sublevel IIB.
The results of the statistical analysis evaluating the im-
pact of several clinical factors on sublevel IIB LN involve-
ment are reported in Table 3. A higher risk for metas-
tasis at sublevel IIB was detected in the parotid gland,
skin of the lateral face and scalp, and unknown primary
tumors (P=.02). The oral cavity was the primary site
among those of the upper aerodigestive tract, with the
highest prevalence of metastasis at this sublevel (10%);
by contrast, the lowest prevalence (2%) was observed in
laryngeal cancers.
A comparison between SCC and non-SCC histologic
type did not reach statistical significance (P=.11). Con-
Table 1. Relationship Between Clinical N (cN) and Pathologic N (pN) Lymph Node Status by Site of the Primary Tumora
Site of Primary Tumor
cN and pN Status
cN0/pN0 cN/pN cN/pN0 cN0/pN
Oral cavity (n=111) 28 (25) 49 (44) 8 (7.5) 26 (23.5)
Larynx (n=92) 35 (38) 33 (36) 9 (10) 15 (16)
Oropharynx (n=32) 5 (24) 20 (54) 2 (10) 5 (12)
Thyroid gland (n=22) 1 (4.5) 20 (91) 0 1 (4.5)
Scalp (n=16) 7 (44) 8 (50) 0 1 (6)
Hypopharynx (n=11) 2 (18) 7 (64) 0 2 (18)
Unknown primary (n=7) 0 7 (100) 0 0
Parotid gland (n=6) 1 (17) 3 (50) 0 2 (33)
aData are given as number (percentage) of patients.
Table 2. Data on the 25 Patients Positive for Metastatic Disease at Sublevel IIB
Patient
No. Site Histotype
Levels
Clinically
Involved
Levels
Histopathologically
Involved
R Neck
Levels
Dissected
L Neck
Levels
Dissected pTNMG
Previous
Treatment
1 Tongue SCC L: II, III, IV L: I, IIA, IIB I-IV I-V T2N2b ecsM0G3 None
2 Cheek, RMT SCC R: I, II R: I, IIA, IIB I-IV NP T3N2b ecsM0G3 None
3 Tongue SCC L: I, II, V L: I, IIA, IIB, V NP I-V T2N2bM0G2 None
4 Tongue SCC R: I R: I, IIA, IIB, V
L: IIA, IV
I-V I-V T4aN2cM0G3 None
5 Tongue SCC Bilateral nodes R: IIA, III
L: IIA, IIB, III, IV
I-V I-V T4aN2cM0G2 None
6 Tongue SCC L: IIA, IIB, III I-V I-IV T3N2bM0G1 None
7 FOM SCC R: II R: IIA, IIB I-V NP T1N2bM0G2 None
8 Tongue SCC R: II
L: II
R: I, IIA, III, IV
L: IIB
I-V I-V T4aN2cM0G2 None
9 Tongue SCC R: II R: IIA, IIB, IV I-V I-III T4aN2bM0G2 None
10 RMT SCC N1 R: IB, IIB, III I-V NP T4aN2bM0G2 None
11 Inferior gingiva SCC L: IB L: IB, IIB NP I-V T4aN2bM0G2 None
12 Scalp Melanoma L: II L: IIB, nucha NP II-V T4aN2bM1 None
13 Scalp Melanoma R: II, V R: IIB, V II-V NP T0N2bM0 Surgery
14 Scalp SCC L: II L: IIA, IIB NP II-V T0N2bM0 Surgery
15 Scalp SCC R: II R: IIA, IIB, IV II-V NP T3N2bM0G3 None
16 Tongue base SCC Bilateral nodes R: IIA, V
L: IIB, III, IV
I-V II-V T3N2cM0G3 None
17 Tongue base SCC L: IIB NP II-V T3N1M0G2 None
18 Supraglottis SCC L: II, III, IV L: IIA, IIB II-V I-V T3N2b ecsM0G3 None
19 Glottis (transglottic) SCC R: IIB II-IVVI NP T3N1M0G3 None
20 Parotid gland SCC L: II, V L: IIA, IIB, V NP II-V T4aN2b
ecsM0G1
None
21 Parotid gland AC R: II, III, V R: IIA, IIB, V I-V NP T4aN2b ecsM0 None
22 Thyroid gland Papillary R: II, III, IV
L: II, III, IV
R: IIB, III, IV, VI
L: IIA, IIB, III, IV
II-VVI II-IVVI T4aN1bM0 None
23 Thyroid gland Papillary R: III R: IIA, IIB, III II-III NP T0N2bM0 Surgery
24 Hypopharynx SCC L: II, III L: IIA, IIB II-V II-V T4aN2bM0G3 None
25 Unknown SCC R: II
L: II
R: IIA, IIB
L: IIA
I-V II-V TxN2cM0 None
Abbreviations: AC, adenocarcinoma; ecs, extracapsular spread; FOM, floor of mouth; L, left side; NP, not performed; pTNMG, pathologic TNM and grading;
R, right side; RMT, retromolar trigone; SCC, squamous cell carcinoma.
(REPRINTED) ARCH OTOLARYNGOL HEAD NECK SURG/VOL 133 (NO. 9), SEP 2007 WWW.ARCHOTO.COM
899
©2007 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universita degli di Milano User  on 03/28/2019
versely, when all different histotypes (SCC, adenocarci-
noma, melanoma, medullary, and papillary carcinoma)
were considered, the results paralleled those obtained by
analysis of primary sites (P=.02). This probably reflects
the preference of the different histologic types for spe-
cific sites.
Moreover, the possibility to find a metastatic local-
ization at sublevel IIB in a patient without clinical evi-
dence of LNmetastasis (cN0)was significantly lower than
the probability of the same finding in patients staged as
cN (P .001). When considering synchronous meta-
static involvement of sublevel IIA and IIB, in our series,
this findingwas observed in 65% (17 of 26)NDs and 63%
(10 of 16) NDs of all head and neck primary tumors and
SCCs of the upper aerodigestive tract, respectively, al-
though the finding was nonsignificant (P=.08).
COMMENT
The pN status is generally considered the most impor-
tant prognostic factor in patients with head and neck can-
cer and, in fact, the presence of nodal metastasis is esti-
mated to decrease determinate survival by about 50%.21,22
Nevertheless, ND is a surgical procedure with remark-
able sequelae that can influence the residual quality of
life. Shoulder disability is one of themost importantmor-
bidities traditionally associated with radical ND charac-
terized by shoulder drop, scapular flaring, pain, andweak-
ness. A large spectrumof different procedures is presently
available for treatment of LN metastasis, but the ana-
tomic preservation of the spinal accessory nerve is not
always associatedwith normal shoulder function. In fact,
only 70% to 75% of patients who underwent to nerve-
sparing dissections did not report any shoulder disabil-
ity.23,24 The clearance of the submuscular recess inevita-
bly causes mechanical traction and ischemic trauma on
the cranial portion of the spinal accessory nerve run-
ning from the skull base to its entrance into the sterno-
cleidomastoid muscle. In fact, the vascular supply to the
nerve originates from the surrounding fat tissue with a
segmental pathway, with unavoidable ischemic insult
when dissection of both sublevels IIA and IIB is per-
formed. The analysis of our data and review of the lit-
erature on the prevalence of sublevel IIB metastasis for
head and neck SCC and non-SCCs (Table 4) suggests
that for a specific subset of patients dissection of sub-
level IIB could be reasonably avoided with the intent of
minimizing functional impairment of the shoulder.
Kraus et al7 prospectively evaluated the prevalence of
occult nodal metastasis in selective ND specimens (lev-
els I-III) for oral and oropharyngeal primary tumors, with
only 1 case (2.1%) observed in a patient affected by a
cT3N0 tonsil cancer who had concomitant occult dis-
ease at both sublevels IIA and IIB. Two years later, Talmi
et al8 studied a series of patients with different head and
neck primary tumors and attempted to define risk fac-
tors for metastasis involving LNs of the submuscular re-
cess. Based on the observation of metastasis at this level
in only 4 patients with cN2-cN3 tumors (3.9%), they con-
cluded that dissection of this lymphatic station could be
avoided in elective NDs. In 2 of the 4 cases, the oral cav-
ity was the site of the primary tumor. Chone et al9 re-
ported SCC metastatic spread to sublevel IIB in 6.5% of
NDs, which was always in conjunction with other lym-
Table 3. Analysis by Pearson ² Test or Fisher Exact Test
of the Impact of 9 Variables on the Prevalence
of Sublevel IIB Metastatic Involvement
Factor
Prevalence of IIB metastasis,
No./Total No. (%)
P
Value
Institution in Italy
Brescia 11/141 (8)
.49Milan 12/117 (10)
Rome 2/39 (5)
Sex
Male 17/230 (7)
.23Female 8/67 (12)
Site
Unknown 1/7 (14)
.02
Oral cavity 11/111 (10)
Skin/scalp 4/16 (25)
Hypopharynx 1/11 (9)
Larynx 2/92 (2)
Oropharynx 2/32 (6)
Parotid gland 2/6 (33)
Thyroid gland 2/22 (9)
Histotype (1)
SCC 20/267 (8)
.11Non-SCC 5/30 (17)
Histotype (2)
SCC 20/267 (8)
.02
Adenocarcinoma 1/4 (25)
Melanoma 2/4 (50)
Medullary carcinoma 0/7
Papillary carcinoma 2/15 (13)
pT status
pT0 3/29 (10)
.13
pT1 0/33
pT2 3/69 (4)
pT3 6/75 (8)
pT4 12/82 (15)
pTx 1/7 (14)
cN status
cN0 3/131 (2)
 .001cN 22/166 (13)
Lower level involved
I 1/17 (6)
.74
II 7/65 (11)
III 3/41 (7)
IV 5/40 (12.5)
V 6/27 (22)
VI 1/7 (14)
Sublevel IIA involved
Yes 19/131 (14)
.08No 4/66 (6)
Ipsilateral involved levels
1 Level 8/107 (7)
.15
2 Levels 10/55 (18)
3 Levels 4/23 (17)
4 Levels 1/9 (11)
5 Levels 0/3
Previous surgical treatment
on the site of primary
Yes 2/32 (6)
 .99No 23/265 (9)
Abbreviations: cN, clinical N; SCC, squamous cell carcinoma;
pN, pathologic N;
pT, pathologic T.
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phatic localizations, with 1 case only of occult disease.
They concluded that dissection of the “apex” is espe-
cially warranted in patients with cN tumors and pha-
ryngeal lesions. The limitations of that study were its ret-
rospective nature and the tagging of the sublevel IIBmade
on the ND specimen.
Silverman et al,12 considering SCC of all head and
neck sites, found metastatic localization at sublevel IIB
in 4 NDs (4.4%), but only 1 of these cases (1.6%) was
clinically staged as N0 and therefore affected by occult
metastasis. They reported a higher prevalence of sub-
level IIB metastasis in patients with advanced pN sta-
tus (P= .003) and in those with metastatic disease
involving sublevel IIA (P=.001). They concluded that
sublevel IIB fat pad dissection could be avoided during
elective NDs or for limited nodal disease not involving
sublevel IIA.
In one of the most extensive series reported in the lit-
erature, Corlette et al15 demonstrated that the preva-
lence of sublevel IIB metastasis may increase as high as
18.7% because of the inclusion of the parotid gland and
skin of the lateral face and the scalp among the primary
sites considered, with overall values of 50% for both sites.
In contrast, no cases of laryngeal and hypopharyngeal pri-
mary tumors with sublevel IIB metastatic spread were
reported.
In 2001, Talmi and coworkers10 expanded their
experience on the issue, focusing on non-SCC of the
head and neck region. The sites analyzed are listed in
Table 4, and the prevalence of sublevel IIB metastasis
was 16%. Most of the cases were cN (78%), and at
least 1 other level was always involved in tumor spread.
In the absence of statistical analysis, it was concluded
that in the case of cN primary tumors of the parotid
and thyroid glands, with a prevalence of submuscular
recess metastatic spread of 43% and 11%, respectively,
sublevel IIB dissection should be strongly advocated.
This concept was also confirmed by our data: in fact,
91% of thyroid gland and 50% of parotid gland primary
tumors were cN, with a prevalence of sublevel IIB
metastasis of 33.3% and 8.7%, respectively. Whenever
primary tumors arising from the parotid gland, the skin
of the lateral face, and the scalp were included in the
analysis, the prevalence of submuscular recess meta-
static spread increased, not only because of the high per-
centage of cN cases10,15 but also because, indepen-
dently of histologic type, this LN echelon is one of the
first involved by tumor spread from these specific sites.20
Several reports have specifically focused on laryn-
geal primary tumors, considering both elective and
therapeutic settings.11,13,17,18 Exclusive sublevel IIB
metastatic localization was detected in 1 specimen
Table 4. Metastatic Involvement of Sublevel IIB: Review of the Literature
Source
Type
of Study
No.
of NDs
Type
of NDs Sites Histotype
IIB, No.
(%)
Exclusive
IIB, No. Remarks
Kraus et al,7 1996 Prospective 47 Elective OC, OP SCC 1 (2.1) 0 . . .
Talmi et al,8 1998 Prospective 102 Elective and
therapeutic
OC, OP, L, S,
UP, others
SCC 4 (3.9) 0 . . .
Chone et al,9 2000 Retrospective 62 Elective and
therapeutic
OC, OP, HP, L,
UP
SCC 4 (6.5) 0 Significant correlation between IIB
Mets and IIA-III Mets (P .05)
Talmi et al,10 2001 Prospective 37 Elective and
therapeutic
TG, PG, S,
others
Non-SCC 6 (16) 0 100% Of cases with IIA Mets also
reported IIB Mets
Koybasiog˘lu et al,11 2002 Prospective 53 Elective and
therapeutic
L SCC 0 (0) 0 . . .
Silverman et al,12 2003 Prospective 90 Elective and
therapeutic
OC, OP, HP, L,
UP, others
SCC 4 (4.4) 0 Significant correlation between IIB
Mets and high pN status
(P=.003) and between IIB Mets
and IIA Mets (P=.001)
Coskun et al,13 2004 Prospective 113 Elective L SCC 0 0 . . .
Lim et al,14 2004 Prospective 74 Elective OC SCC 4 (5.4) 0 . . .
Corlette et al,15 2005 Prospective 160 Elective and
therapeutic
OC, OP, HP, L,
S, PG
SCC 30 (18.7) 10 (S, PG) Significant correlation between IIB
Mets and S and PG primary
tumors (P .05)
Elsheikh et al,16 2005 Prospective 74 Elective OC SCC 5 (6.7) 0 Molecular analysis of lymphatic
tissue
Elsheikh et al,17 2006 Prospective 51 Elective L SCC 1 (2) 1 (L) Molecular analysis of lymphatic
tissue
Lim et al,18 2006 Prospective 125 Elective and
therapeutic
L SCC 8 (6.4) 0 Significant correlation between IIB
Mets and cN status (P .001)
and between IIB Mets and
presence of other metastatic LNs
(P=.001)
Present series, 2006 Prospective 443 Elective and
therapeutic
OC, OP, HP, L,
PG, TG, S,
UP
SCC and
non-SCC
26 (5.6) 2 (1 OP, 1 L) Significant correlation between IIB
Mets and cN status (P .001)
and IIB Mets and the site of
primary tumor (P=.02)
Abbreviations: cN, clinical N; HP, hypopharynx; L, larynx; Mets, metastasis; LNs, lymph nodes; NDs, neck dissections; OC, oral cavity; OP, oropharynx;
PG, parotid gland; pN, pathologic N; S, skin/scalp; SCC, squamous cell carcinoma; TG, thyroid gland; UP, unknown primary.
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(2%) from 51 elective NDs after molecular analysis by
nested reverse transcription polymerase chain reaction
for cytokeratin 19 and cytokeratin 20.17 In contrast, in
a larger series of laryngeal primary tumors, a 6.4%
prevalence of sublevel IIB involvement was detected,
1% for patients scheduled for elective NDs and 30%
for those scheduled for therapeutic NDs, with no cases
of exclusive sublevel IIB localization.18 These data pro-
vide a high degree of evidence for the negligible
involvement of submuscular recess LNs in patients
scheduled for elective ND for laryngeal primary
tumors. In our series, considering the 50 patients
affected by cN0 laryngeal cancer, only a single case
(2%) of exclusive sublevel IIB metastatic localization
was observed (patient 19 in Table 2).
There are only 2 studies that have focused on SCC
of the oral cavity: in both reports, only elective NDs
were evaluated with a relatively high frequency of sub-
level IIB occult localization (5.4% and 6.7%, respec-
tively).14,16 Our experience also indicates that the oral
cavity has the highest overall prevalence of sublevel
IIB metastasis (10%) among SCCs arising from the
upper aerodigestive tract (Table 3), but with a lower
prevalence in the cN0 setting (2%) compared with
those reported in the literature.
In conclusion, ourmulticentric prospective study ana-
lyzed a wide range of head and neck cancers with squa-
mous and nonsquamous histologic type, involving most
primary sites (except paranasal sinuses and nasophar-
ynx), with the intent to provide information on sub-
level IIB metastatic involvement. The data collected re-
inforce the concept already reported in the literature that
sublevel IIB dissection is strongly recommended for all
patients with cN tumors and in those with a tumor of
the parotid gland, skin of the lateral face, and scalp sched-
uled for elective ND.
A major limitation in our study is the small number
of patients considered for some specific sites, such as
the hypopharynx and parotid gland, which can be
considered a source of bias for statistical analysis. The
reasons for this distribution can be identified in our
management policy, which mainly includes chemora-
diation for the primary treatment of hypopharyngeal
cancer and rarely requires ND for parotid primary
tumors.
Furthermore, patients with cN0 laryngeal primary tu-
mors scheduled for elective ND appeared to be the ideal
population for further studies aimed at prospective as-
sessment of whether preservation of sublevel IIB is as-
sociatedwith an improvement in shoulder function using
clinical and electromyographic evaluations.
Data from the first preliminary report concerning
this issue did not provide encouraging results, with no
functional shoulder improvement and a similar axonal
deterioration in patients who did not undergo sublevel
IIB dissection.25 However, the small number of
patients (n=10) and the early timing of postoperative
control (third postoperative month) suggest that fur-
ther investigations on a large cohort of patients with
adequate timing for postoperative evaluation are
required. Moreover, additional measures could be
adopted to reduce shoulder disability, such as meticu-
lous preservation, when possible, of cervical branches
(C2-C4) during ND and a systematic postoperative
physical therapy.
Submitted for Publication: August 7, 2006; final revi-
sion receivedDecember 19, 2006; accepted April 6, 2007.
Correspondence: Andrea Bolzoni Villaret, MD, Depart-
ment ofOtorhinolaryngology,University of Brescia, Piazza
Spedali Civili 1, 25123 Brescia, Italy (dr.bolton@libero
.it).
Author Contributions: Dr Bolzoni Villaret had full ac-
cess to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data
analysis. Study concept and design:Bolzoni Villaret, Piazza,
Peretti, Chiesa, and Nicolai. Acquisition of data: Bolzoni
Villaret, Calabrese, Ansarin, Pellini, and Spriano. Analy-
sis and interpretation of data: Piazza.Drafting of the manu-
script: Bolzoni Villaret and Peretti.Critical revision of the
manuscript for important intellectual content: Piazza,
Calabrese, Ansarin, Chiesa, Pellini, Spriano, andNicolai.
Administrative, technical, and material support: Ansarin,
Chiesa, Pellini, Spriano, and Nicolai. Study supervision:
BolzoniVillaret, Piazza, Peretti, Calabrese,Chiesa, Spriano,
and Nicolai.
Financial Disclosure: None reported.
Previous Presentation: This study was presented at the
Annual Meeting and Research Workshop on the Biol-
ogy, Prevention, and Treatment of Head and Neck Can-
cer; August 17-20, 2006; Chicago, Illinois.
REFERENCES
1. Crile GW. On the surgical treatment of cancer of the head and neck: with a
summary of one hundred and twenty-one operations performed upon one
hundred and five patients. Trans South Surg Gynecol Assoc. 1905;18:
108-127.
2. Crile GW. Excision of cancer of the head and neck—with special reference to the
plan of dissection based on one hundred and thirty-two operations. JAMA. 1906;
47:1780-1786.
3. Martin HE, Del Valle B, Ehrlich H, et al. Neck dissection. Cancer. 1951;4(3):
441-499.
4. Suarez O. El problema de las metastasis linfaticas y alejadas del cancer de lar-
inge e hipofaringe. Rev Otorrinolaringol. 1963;23:83-99.
5. Bocca E. Supraglottic laryngectomy and functional neck dissection. J Laryngol
Otol. 1966;80(8):831-836.
6. Shah JP. Patterns of cervical lymph node metastasis from squamous cell car-
cinomas of the upper aerodigestive tract. Am J Surg. 1990;160(4):405-409.
7. Kraus DH, Rosemberg DB, Davidson BJ, et al. Supraspinal accessory lymph node
metastases in suprahomohyoid neck dissection. Am J Surg. 1996;172(6):
646-649.
8. Talmi YP, Hoffman HT, Horowitz Z, et al. Patterns of metastases to the upper
jugular lymph nodes (the “submuscular recess”). Head Neck. 1998;20(8):
682-686.
9. Chone CT, Crespo AN, Rezende AS, Carvalho DS, Altemani A. Neck lymph node
metastases to the posterior triangle apex: evaluation of clinical and histopatho-
logical risk factors. Head Neck. 2000;22(6):564-571.
10. Talmi YP, Horowitz Z, Wolf M, et al. Upper jugular lymph nodes (submuscular
recess) in non-squamous-cell cancer of the head and neck: surgical considerations.
J Laryngol Otol. 2001;115(10):808-811.
11. Koybasiog˘lu A, Uslu S, Yilmaz M, Inal E, Ileri F, Asal K. Lymphatic metastasis to
the supraretrospinal recess in laryngeal squamous cell carcinoma. Ann Otol Rhi-
nol Laryngol. 2002;111(1):96-99.
12. Silverman DA, El-Hajj M, Strome S, Esclamado RM. Prevalence of nodal metas-
tases in the submuscular recess (level IIb) during selective neck dissection. Arch
Otolaryngol Head Neck Surg. 2003;129(7):724-728.
13. Coskun HH, Erisen L, Basut O. Selective neck dissection for clinically N0 neck in
laryngeal cancer: is dissection of level IIb necessary?Otolaryngol Head Neck Surg.
2004;131(5):655-659.
(REPRINTED) ARCH OTOLARYNGOL HEAD NECK SURG/VOL 133 (NO. 9), SEP 2007 WWW.ARCHOTO.COM
902
©2007 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universita degli di Milano User  on 03/28/2019
14. Lim YC, Song MH, Kim SC, Kim KM, Choi EC. Preserving level IIb lymph nodes
in elective supraomohyoid neck dissection for oral cavity squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg. 2004;130(9):1088-1091.
15. Corlette TH, Cole IE, Albsoul N, Ayyash M. Neck dissection of level IIb: is it really
necessary? Laryngoscope. 2005;115(9):1624-1626.
16. Elsheikh MN, Mahfouz ME, Elsheikh E. Level IIb lymph nodes metastasis in elec-
tive supraomohyoid neck dissection for oral cavity squamous cell carcinoma: a
molecular-based study. Laryngoscope. 2005;115(9):1636-1640.
17. Elsheikh MN, Mahfouz ME, Salim EI, Elsheikh EA. Molecular assessment of neck
dissections supports preserving level IIB lymph nodes in selective neck dissec-
tion for laryngeal squamous cell carcinoma with a clinically negative neck. ORL
J Otorhinolaryngol Relat Spec. 2006;68(3):177-184.
18. Lim YC, Lee JS, Koo BS, Choi EC. Level IIb lymph node metastasis in laryngeal
squamous cell carcinoma. Laryngoscope. 2006;116(2):268-272.
19. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer StagingManual. 6th ed. New
York, NY: Springer; 2002.
20. Robbins KT, ClaymanG, Levine PA, et al; American Head and Neck Society; Ameri-
can Academy of Otolaryngology–Head and Neck Surgery. Neck dissection clas-
sification update: revisions proposed by the American Head and Neck Society
and the American Academy of Otolaryngology–Head and Neck Surgery. Arch Oto-
laryngol Head Neck Surg. 2002;128(7):751-758.
21. Shah JP, Andersen PE. Evolving role of modifications in neck dissection for oral
squamous carcinoma. Br J Oral Maxillofac Surg. 1995;33(1):3-8.
22. Puri SK, Fan CY, Hanna E. Significance of extracapsular lymph node metastases
in patients with head and neck squamous cell carcinoma. Curr Opin Otolaryngol
Head Neck Surg. 2003;11(2):119-123.
23. Leipzig B, Suen JY, English JL, Barnes J, Hooper M. Functional evaluation of the
spinal accessory nerve after neck dissection. Am J Surg. 1983;146(4):526-530.
24. Cappiello J, Piazza C, Giudice M, De Maria G, Nicolai P. Shoulder disability after
different selective neck dissections (levels II-IV versus levels II-V): a compara-
tive study. Laryngoscope. 2005;115(2):259-263.
25. Koybasiog˘lu A, Bora Tokcaer A, Inal E, Ulsu S, Kocak T, Ural A. Accessory nerve
function in lateral selective neck dissection with undissected level IIb.ORL J Oto-
rhinolaryngol Relat Spec. 2006;68(2):88-92.
(REPRINTED) ARCH OTOLARYNGOL HEAD NECK SURG/VOL 133 (NO. 9), SEP 2007 WWW.ARCHOTO.COM
903
©2007 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Universita degli di Milano User  on 03/28/2019
